NEW YORK (GenomeWeb) – Genomic Vision announced today that it has partnered with Australia's Children’s Medical Research Institute (CMRI) to develop an assay that will enable research into the role of telomere length on cardiovascular disease, cancer, and other complex disorders.
Under the terms of the deal, the partners will develop the assay using Genomic Vision's DNA combing technology — which involves stretching coils of DNA into straight chains to enable direct, high-resolution analysis of targeted areas of the human genome — and CMRI's extensive clinical cohorts. Additional terms were not disclosed.
"Our new DNA combing technology will be the only one that enables the characterization and the distribution of any of the 92 telomeres in each cell," Stephane Altaba, executive vice president of corporate development at Genomic Vision, said in a statement. "With this huge competitive advantage, we believe that our test will become the reference assay in telomere length measurement."